France Human Growth Hormone Market Size, Share, and COVID-19 Impact Analysis, By Application (Turner Syndrome, Idiopathic Short Stature, Prader-Willi Syndrome, Small for Gestational Age, Growth Hormone Deficiency, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Specialty Pharmacy, and Others), and France Human Growth Hormone Market Insights, Industry Trend, Forecasts to 2035

France Human Growth Hormone Market Insights Forecasts to 2035

• The France Human Growth Hormone Market Size Was Estimated at USD 299.6 Million in 2024
• The France Human Growth Hormone Market Size is Expected to Grow at a CAGR of Around 13.03% from 2025 to 2035
• The France Human Growth Hormone Market Size is Expected to Reach USD 1152.6 Million by 2035

According to a research report published by Spherical Insights & Consulting, The France Human Growth Hormone Market Size is anticipated to reach USD 1152.6 Million by 2035, Growing at a CAGR of 13.03% from 2025 to 2035. The France human growth hormone market is driven by increasing diagnoses of growth hormone disorders, strong healthcare access and reimbursement, and advancements in recombinant and biosimilar HGH therapies that improve treatment availability and effectiveness.

Market Overview

The France human growth hormone market is the market for therapeutic human growth hormones used for the treatment of growth hormone deficiency and related disorders in children and adults, such as pediatric growth hormone deficiency, Turner syndrome, chronic kidney disease, and adult growth hormone deficiency. It covers the use of recombinant HGH, biosimilars, and delivery systems, which are distributed through hospitals, specialty clinics, and pharmacies throughout France. The market is coming from the increased diagnoses of growth disorders, elevated awareness, and better early intervention, as well as from the development of recombinant and biosimilar HGH drugs that provide safer, more effective, and more convenient treatment options. There continues to be a solid level of market growth because of the strong ongoing demand from both pediatric and adult populations.

The France human growth hormone market is influenced by increasing recognition and diagnosis of growth hormone deficiency (GHD) and conditions related to it, such as Turner syndrome, idiopathic short stature, and small for gestational age. In France, both children with growth disorders and adults with GHD are given considerable clinical attention. Adult GHD is estimated to affect around 3,000 people in France, and there are also several hundred children receiving treatment for growth disorders such as Turner syndrome. This patient demand highlights the need for HGH therapies since most of the individuals concerned require long-term treatment in order to enhance their growth results and quality of life. The France human growth hormone market has strong potential that comes from better diagnostics, increased awareness, and earlier intervention, as well as the growing use of biosimilars and advanced delivery systems. The demand for adult HGH is supported by the government offering incentives such as R&D tax credits, which can cover up to 30% of the expenses, and health innovation investments of over €7 billion. These are additional factors that drive innovation and the market growth.

Report Coverage

This research report categorizes the market for the France human growth hormone market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France human growth hormone market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France human growth hormone market.

Driving Factors

The France human growth hormone (HGH) market is driven by factors such as the increasing diagnosis of growth hormone deficiency in children and adults, the spreading awareness and early treatment, and the expanding use of recombinant and biosimilar HGH therapies. Moreover, the excellent public healthcare coverage and reimbursement policies, the elderly population suffering from hormonal disorders, and the government's help for biotech research are other main factors that contribute to a gradual market development.

Restraining Factors

France human growth hormone market is restrained by the high price of therapy, strict prescription and eligibility criteria, and concerns about long-term safety and side effects. Lack of awareness in some adult segments, risk of misuse or off-label use, and rigorous regulatory and reimbursement controls also hamper the market's faster growth.

Market Segmentation

The France human growth hormone market share is classified into application and distribution channel.

• The growth hormone deficiency segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France human growth hormone market is segmented by application into Turner syndrome, idiopathic short stature, Prader-Willi syndrome, small for gestational age, growth hormone deficiency, and others. Among these, the growth hormone deficiency segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The growth hormone deficiency segment is growing because it represents the most commonly diagnosed indication for HGH therapy in both children and adults in France. Improved diagnostic methods, increased awareness among healthcare professionals, and strong reimbursement support enable early and long-term treatment, driving higher adoption and sustained demand.

• The hospital pharmacy segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The France human growth hormone market is segmented by distribution channel into hospital pharmacy, retail pharmacy, online pharmacy, specialty pharmacy, and others. Among these, the hospital pharmacy segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The hospital pharmacy segment is growing because hospitals are the primary centers for diagnosis, initiation, and monitoring of HGH therapy in France. Prescriptions are typically issued by specialists in hospital settings, and controlled dispensing and patient follow-up make hospital pharmacies the preferred distribution channel, driving higher revenue and continued growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France human growth hormone market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc.
• Novo Nordisk A/S
• Eli Lilly and Company
• Merck KGaA (EMD Serono)
• Sandoz International GmbH (Novartis AG)
• Ferring Pharmaceuticals
• Ipsen S.A.
• F. Hoffmann-La Roche Ltd.
• Teva Pharmaceutical Industries Ltd.
• Ascendis Pharma A/S
• AnkeBio Co., Ltd.
• LG Chem / LG Life Sciences
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the France human growth hormone market based on the below-mentioned segments:

France Human Growth Hormone Market, By Application

• Turner Syndrome
• Idiopathic Short Stature
• Prader-Willi Syndrome
• Small for Gestational Age
• Growth Hormone Deficiency
• Others

France Human Growth Hormone Market, By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Specialty Pharmacy
• Others